Intralipid and IVIg: what these therapies are, and where the evidence stands

Intralipid infusion and intravenous immunoglobulin (IVIg) therapy are two immune treatments offered for recurrent implantation failure or recurrent pregnancy loss where an immune cause is suspected. Both have plausible biological mechanisms. Both have evidence that is more mixed than the marketing around them suggests. Both deserve a careful read before you sign up.

What intralipid is

Intralipid is a 20 percent fat emulsion (soybean oil, egg phospholipids, glycerol) originally used as parenteral nutrition. In reproductive immunology it is administered by intravenous infusion before embryo transfer and during early pregnancy, on the hypothesis that it modulates natural killer (NK) cell activity and tilts the immune environment toward implantation tolerance.

What the evidence shows for intralipid

Some observational studies and small randomised trials suggest improvement in live-birth rates among patients with elevated NK cell activity or recurrent implantation failure. Other studies find no effect. The largest meta-analyses to date find a small possible benefit in selected patients but caution against routine use. It is not currently endorsed by major fertility societies as standard of care.

What IVIg is

Intravenous immunoglobulin is pooled antibodies from thousands of human donors, administered intravenously. In reproductive immunology it is given before transfer and through early pregnancy on the hypothesis that it broadly modulates the maternal immune response, suppresses NK cell activity, and reduces antibody-mediated rejection of the embryo.

What the evidence shows for IVIg

The evidence for IVIg in recurrent implantation failure or recurrent loss is mixed, with some positive trials and some negative. Cochrane and large meta-analyses have not consistently demonstrated benefit. The treatment is expensive (often Rs 80,000 to 1,50,000 per cycle in India), carries small risks of allergic reaction or infection, and depletes a finite blood-product resource.

Where these therapies might still be considered

In specific subsets – patients with documented antiphospholipid syndrome on the standard heparin/aspirin protocol who continue to lose pregnancies; patients with three or more good-quality euploid transfer failures and elevated NK markers – some clinicians offer intralipid or IVIg as last-line therapy under informed consent. These are reasonable, individualised decisions, not standard recommendations.

How to think about the cost-benefit

If a clinic recommends either therapy, ask: what is my specific indication, what does the published evidence suggest the effect size to be in patients like me, what is the cost, and what would we do instead. If the alternative is an additional good-quality transfer with adjusted timing or a different protocol, that may be a stronger investment than an unproven immune therapy.

Questions worth asking your doctor

• What is my specific indication for intralipid or IVIg, and what is the evidence base in that indication?
• What other interventions would we try first, or instead?
• What is the realistic effect size on my live-birth probability?
• What are the costs, the side effects, and how many cycles of treatment are planned?

This essay is educational. Every patient’s situation is different – the right plan is shaped in conversation with a fertility specialist who knows the full picture.